Literature DB >> 8524852

Topoisomerase IV is a target of quinolones in Escherichia coli.

A B Khodursky1, E L Zechiedrich, N R Cozzarelli.   

Abstract

We have demonstrated that, in Escherichia coli, quinolone antimicrobial agents target topoisomerase IV (topo IV). The inhibition of topo IV becomes apparent only when gyrase is mutated to quinolone resistance. In such mutants, these antibiotics caused accumulation of replication catenanes, which is diagnostic of a loss of topo IV activity. Mutant forms of topo IV provided an additional 10-fold resistance to quinolones and prevented drug-induced catenane accumulation. Drug inhibition of topo IV differs from that of gyrase. (i) Wild-type topo IV is not dominant over the resistant allele. (ii) Inhibition of topo IV leads to only a slow stop in replication. (iii) Inhibition of topo IV is primarily bacteriostatic. These differences may result from topo IV acting behind the replication fork, allowing for repair of drug-induced lesions. We suggest that this and a slightly higher intrinsic resistance of topo IV make it secondary to gyrase as a quinolone target. Our results imply that the quinolone binding pockets of gyrase and topo IV are similar and that substantial levels of drug resistance require mutations in both enzymes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8524852      PMCID: PMC40490          DOI: 10.1073/pnas.92.25.11801

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication.

Authors:  D E Adams; E M Shekhtman; E L Zechiedrich; M B Schmid; N R Cozzarelli
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

Review 2.  DNA topoisomerases: why so many?

Authors:  J C Wang
Journal:  J Biol Chem       Date:  1991-04-15       Impact factor: 5.157

3.  New topoisomerase essential for chromosome segregation in E. coli.

Authors:  J Kato; Y Nishimura; R Imamura; H Niki; S Hiraga; H Suzuki
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

4.  Increased production of a knotted form of plasmid pBR322 DNA in Escherichia coli DNA topoisomerase mutants.

Authors:  K Shishido; N Komiyama; S Ikawa
Journal:  J Mol Biol       Date:  1987-05-05       Impact factor: 5.469

5.  Cloning and simplified purification of Escherichia coli DNA gyrase A and B proteins.

Authors:  K Mizuuchi; M Mizuuchi; M H O'Dea; M Gellert
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

6.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

Authors:  K M Tewey; T C Rowe; L Yang; B D Halligan; L F Liu
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

8.  Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

Authors:  P Heisig; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS.

Authors:  W A GOSS; W H DEITZ; T M COOK
Journal:  J Bacteriol       Date:  1965-04       Impact factor: 3.490

10.  Rapid evaluation of topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo.

Authors:  C G Shin; J M Strayer; M A Wani; R M Snapka
Journal:  Teratog Carcinog Mutagen       Date:  1990
View more
  133 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Analysis of topoisomerase function in bacterial replication fork movement: use of DNA microarrays.

Authors:  A B Khodursky; B J Peter; M B Schmid; J DeRisi; D Botstein; P O Brown; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 4.  Topological challenges to DNA replication: conformations at the fork.

Authors:  L Postow; N J Crisona; B J Peter; C D Hardy; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

5.  Promoter protection by a transcription factor acting as a local topological homeostat.

Authors:  Mark Rochman; Michal Aviv; Gad Glaser; Georgi Muskhelishvili
Journal:  EMBO Rep       Date:  2002-03-15       Impact factor: 8.807

6.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

7.  Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.

Authors:  Christine D Hardy; Nicholas R Cozzarelli
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Topoisomerase IV, alone, unknots DNA in E. coli.

Authors:  R W Deibler; S Rahmati; E L Zechiedrich
Journal:  Genes Dev       Date:  2001-03-15       Impact factor: 11.361

9.  Preferential relaxation of positively supercoiled DNA by E. coli topoisomerase IV in single-molecule and ensemble measurements.

Authors:  N J Crisona; T R Strick; D Bensimon; V Croquette; N R Cozzarelli
Journal:  Genes Dev       Date:  2000-11-15       Impact factor: 11.361

10.  Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.

Authors:  Katherine A Hurley; Thiago M A Santos; Molly R Fensterwald; Madhusudan Rajendran; Jared T Moore; Edward I Balmond; Brice J Blahnik; Katherine C Faulkner; Marie H Foss; Victoria A Heinrich; Matthew G Lammers; Lucas C Moore; Gregory D Reynolds; Galen P Shearn-Nance; Brian A Stearns; Zi W Yao; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.